These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 33634954)
1. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions. Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954 [TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Rafei H; Daher M; Rezvani K Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984 [TBL] [Abstract][Full Text] [Related]
3. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives]. Nguyen S; Lacan C; Roos-Weil D Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811 [TBL] [Abstract][Full Text] [Related]
4. IPSC-derived CAR-NK cells for cancer immunotherapy. Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511 [TBL] [Abstract][Full Text] [Related]
5. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients. Lu SJ; Feng Q Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715 [TBL] [Abstract][Full Text] [Related]
6. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells. Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731 [TBL] [Abstract][Full Text] [Related]
7. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells. Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684 [TBL] [Abstract][Full Text] [Related]
13. Clinical development of natural killer cells expressing chimeric antigen receptors. Golden RJ; Fesnak AD Transfus Apher Sci; 2021 Feb; 60(1):103065. PubMed ID: 33468407 [TBL] [Abstract][Full Text] [Related]
14. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies. Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710 [TBL] [Abstract][Full Text] [Related]
15. Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy. Siegler EL; Zhu Y; Wang P; Yang L Cell Stem Cell; 2018 Aug; 23(2):160-161. PubMed ID: 30075127 [TBL] [Abstract][Full Text] [Related]
16. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]